AU2013318146B2 - Drug delivery systems and methods for treatment of bladder voiding dysfunction|and other lower urinary tract disorders by using trospium - Google Patents

Drug delivery systems and methods for treatment of bladder voiding dysfunction|and other lower urinary tract disorders by using trospium Download PDF

Info

Publication number
AU2013318146B2
AU2013318146B2 AU2013318146A AU2013318146A AU2013318146B2 AU 2013318146 B2 AU2013318146 B2 AU 2013318146B2 AU 2013318146 A AU2013318146 A AU 2013318146A AU 2013318146 A AU2013318146 A AU 2013318146A AU 2013318146 B2 AU2013318146 B2 AU 2013318146B2
Authority
AU
Australia
Prior art keywords
trospium
bladder
medicament
urine
treatment period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013318146A
Other languages
English (en)
Other versions
AU2013318146A1 (en
Inventor
Dennis GIESING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taris Biomedical LLC
Original Assignee
Taris Biomedical LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical LLC filed Critical Taris Biomedical LLC
Publication of AU2013318146A1 publication Critical patent/AU2013318146A1/en
Application granted granted Critical
Publication of AU2013318146B2 publication Critical patent/AU2013318146B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
AU2013318146A 2012-09-18 2013-09-18 Drug delivery systems and methods for treatment of bladder voiding dysfunction|and other lower urinary tract disorders by using trospium Ceased AU2013318146B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261702576P 2012-09-18 2012-09-18
US61/702,576 2012-09-18
PCT/US2013/060479 WO2014047221A1 (en) 2012-09-18 2013-09-18 Drug delivery systems and methods for treatment of bladder voiding dysfunction|and other lower urinary tract disorders by using trospium

Publications (2)

Publication Number Publication Date
AU2013318146A1 AU2013318146A1 (en) 2015-03-19
AU2013318146B2 true AU2013318146B2 (en) 2018-05-10

Family

ID=49301639

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013318146A Ceased AU2013318146B2 (en) 2012-09-18 2013-09-18 Drug delivery systems and methods for treatment of bladder voiding dysfunction|and other lower urinary tract disorders by using trospium

Country Status (13)

Country Link
US (2) US10500200B2 (https=)
EP (1) EP2897616A1 (https=)
JP (2) JP6600256B2 (https=)
KR (1) KR102141433B1 (https=)
CN (2) CN104684556A (https=)
AU (1) AU2013318146B2 (https=)
BR (1) BR112015005351A2 (https=)
CA (1) CA2883855C (https=)
IL (1) IL237498B (https=)
MX (2) MX379066B (https=)
RU (1) RU2670749C9 (https=)
SG (1) SG11201502104YA (https=)
WO (1) WO2014047221A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8721621B2 (en) 2009-09-10 2014-05-13 Taris Biomedical, Inc. Systems and methods for deploying devices to genitourinary sites
SG11201501424SA (en) 2012-08-31 2015-03-30 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer comprising oxaliplatin
MX367070B (es) 2012-08-31 2019-08-05 Taris Biomedical Llc Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.
MX379066B (es) * 2012-09-18 2025-03-04 Taris Biomedical Llc Sistemas de administracion de farmaco y metodos para el tratamiento de la disfuncion miccional de la vejiga y otros trastornos del tracto urinario inferior.
LT4124339T (lt) 2014-03-06 2025-11-10 Vaisto įvedimo sistemos ir būdai šlapimo pūslės vėžiui gydyti gemcitabinu
CN106573133B (zh) * 2014-08-19 2020-03-03 加利福尼亚大学董事会 用于局部药物递送的植入物及其使用方法
GB201506526D0 (en) 2015-04-17 2015-06-03 Uropharma Ltd And Synesis Llc Medicinal composition
CN106706832A (zh) * 2015-08-06 2017-05-24 舒泰神（北京）生物制药股份有限公司 一种测定曲司氯铵含量的方法
PT3432970T (pt) 2017-02-01 2021-05-26 Taris Biomedical Llc Dispositivos de administração de fármaco in vivo
BR112020000832A2 (pt) 2017-07-25 2020-07-21 Taris Biomedical Llc métodos para tratar metástase tumoral
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
WO2019217455A1 (en) 2018-05-07 2019-11-14 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
CN112839653A (zh) * 2018-08-01 2021-05-25 塔里斯生物医药公司 使用曲司氯铵治疗膀胱过度活动症的方法
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
AU2020265812B2 (en) * 2019-04-30 2025-08-28 Trigone Pharma Ltd. Formulations and methods for drug instillation into the bladder and treatment of bladder ailments
US11173291B2 (en) 2020-03-20 2021-11-16 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
JP7665645B2 (ja) 2020-03-20 2025-04-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 局所的な薬物送達のための移植可能な薬物送達デバイス
US11344526B2 (en) 2020-03-20 2022-05-31 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11338119B2 (en) 2020-03-20 2022-05-24 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
KR102596697B1 (ko) 2021-05-20 2023-11-01 김정우 바위솔 추출물을 유효성분으로 포함하는 화장품 조성물 및 그 제조 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998430A (en) * 1996-11-27 1999-12-07 Dr. R. Pfleger Chemische Fabrik Gmbh Use of trospium chloride and 2-component system for the same
WO2006101954A2 (en) * 2005-03-17 2006-09-28 Indevus Pharmaceuticals, Inc. Interstitial cystitis treatment
US20120203203A1 (en) * 2011-02-04 2012-08-09 Taris Biomedical, Inc. Implantable device for controlled dissolution and diffusion of low solubility drug

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
US20060058777A1 (en) * 2002-12-11 2006-03-16 Pia Norup Nielsen Urinary catheter device with a pharmaceutically active composition
WO2004064789A2 (en) 2003-01-16 2004-08-05 University Of Rochester Quaternary antimuscarinic compounds for the treatment of bladder diseases
ES2322148T3 (es) 2004-08-11 2009-06-17 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Medicamentos que contienen anticolinergicos para el tratamiento en las vias urinarias.
US7390816B2 (en) 2005-06-21 2008-06-24 Bridge Pharma, Inc. Methods for treating urinary incontinence in patients suffering from memory disorders
DK1933810T3 (da) 2005-08-11 2013-01-28 Childrens Medical Center Intravesikal lægemiddelafgivelsesindretning og fremgangsmåde
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
KR101538748B1 (ko) 2007-12-11 2015-07-22 메사추세츠 인스티튜트 오브 테크놀로지 이식형 의약 투여 장치와 방광과 기타 신체 낭 또는 내강의 치료 방법
EA201170297A1 (ru) 2008-08-09 2011-08-30 Массачусетс Инститьют Оф Текнолоджи Имплантируемое устройство для доставки лекарственных средств и способ лечения мужской мочеполовой системы и окружающих тканей
DK2445570T3 (da) 2009-06-26 2013-02-25 Taris Biomedical Inc Implanterbare lægemiddelafgivelsesindretninger samt fremgangsmåder til deres fremstilling
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
US8721621B2 (en) 2009-09-10 2014-05-13 Taris Biomedical, Inc. Systems and methods for deploying devices to genitourinary sites
PL3884988T3 (pl) 2009-12-17 2025-09-08 Taris Biomedical Llc Urządzenie implantowalne z tolerancją wewnątrzpęcherzową
US20110218488A1 (en) 2010-03-05 2011-09-08 Taris Biomedical, Inc. Systems and Methods for Implanting Devices in the Bladder and Other Genitourinary Sites
US9457176B2 (en) 2010-10-06 2016-10-04 Taris Biomedical Llc Implantable drug delivery device with bladder retention feature
WO2012048114A1 (en) * 2010-10-06 2012-04-12 Taris Biomedical, Inc. Time-selective bioresorbable or collapsible drug delivery systems and methods
JP2014503554A (ja) 2011-01-10 2014-02-13 タリス バイオメディカル，インコーポレイテッド 膀胱痛及び刺激性排尿の持続的治療の使用のためのリドカインレジメン
MX379066B (es) * 2012-09-18 2025-03-04 Taris Biomedical Llc Sistemas de administracion de farmaco y metodos para el tratamiento de la disfuncion miccional de la vejiga y otros trastornos del tracto urinario inferior.
KR102557326B1 (ko) 2013-03-15 2023-07-19 타리스 바이오메디컬 엘엘씨 약물-투과성 구성요소를 가지는 약물 전달 장치

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998430A (en) * 1996-11-27 1999-12-07 Dr. R. Pfleger Chemische Fabrik Gmbh Use of trospium chloride and 2-component system for the same
WO2006101954A2 (en) * 2005-03-17 2006-09-28 Indevus Pharmaceuticals, Inc. Interstitial cystitis treatment
US20120203203A1 (en) * 2011-02-04 2012-08-09 Taris Biomedical, Inc. Implantable device for controlled dissolution and diffusion of low solubility drug

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MICHAELI W et al:, ANNUAL TECHNICAL CONFERENCE - ANTEC 2009, , SOCIETY OF PLASTICS ENGINEERS USA, 2009, Vol. 5, pages 2951-2956, *
VON WALTER M et al: " TROSPIUM CHLORIDE RELEASED FROM INTRAVESICALLY APPLIED PLGA-BASED CARRIERS DECREASES BLADDER CONTRACTILITY IN AN ISOLATED WHOLE PIG BLADDER MODEL", EUROPEAN UROLOGY SUPPLEMENTS, 2009, 230, Vol. 8, no. 4, page 178 *

Also Published As

Publication number Publication date
JP2015529688A (ja) 2015-10-08
CA2883855C (en) 2020-09-15
JP6600256B2 (ja) 2019-10-30
IL237498B (en) 2018-01-31
CN111450093A (zh) 2020-07-28
CA2883855A1 (en) 2014-03-27
BR112015005351A2 (pt) 2017-07-04
IL237498A0 (en) 2015-04-30
RU2015112196A (ru) 2016-11-10
MX2020002465A (es) 2020-07-13
WO2014047221A9 (en) 2015-05-21
SG11201502104YA (en) 2015-05-28
JP2018080208A (ja) 2018-05-24
WO2014047221A1 (en) 2014-03-27
EP2897616A1 (en) 2015-07-29
RU2670749C2 (ru) 2018-10-25
KR20150058271A (ko) 2015-05-28
RU2670749C9 (ru) 2018-12-13
MX2015003110A (es) 2015-06-05
US20150182516A1 (en) 2015-07-02
CN104684556A (zh) 2015-06-03
MX379066B (es) 2025-03-04
AU2013318146A1 (en) 2015-03-19
US20200108057A1 (en) 2020-04-09
KR102141433B1 (ko) 2020-08-05
US11850244B2 (en) 2023-12-26
US10500200B2 (en) 2019-12-10

Similar Documents

Publication Publication Date Title
AU2013318146B2 (en) Drug delivery systems and methods for treatment of bladder voiding dysfunction|and other lower urinary tract disorders by using trospium
KR102157548B1 (ko) 방광암의 치료를 위한 옥살리플라틴을 포함하는 약물 전달 시스템과 방법
KR102383496B1 (ko) 젬시타빈을 포함하는 전립선 질환의 치료를 위한 약물 전달 시스템과 방법
JP2015529688A5 (https=)
RU2013135170A (ru) Схема приема лидокаина для применения в продолжительном лечении боли в мочевом пузыре и раздражения при мочеиспускании
HK40026424A (en) Drug delivery systems and methods for treatment of bladder voiding dysfunction and other lower urinary tract disorders by using trospium
JP2016503406A5 (https=)
HK40042011A (en) Drug delivery systems and methods for treatment of prostate

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired